Sign inCreate account

Report workspace

Add to folder
NCT00482079COMPLETEDanonymous

A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled Dose-Range Finding Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

Sponsor

Source record

Merck Sharp & Dohme LLC

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Dipeptidyl peptidase-4 (DPP-4) inhibition

Indication / condition

AI-normalized

Diabetes Mellitus, Type II

Intervention

Source record

MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks

Source & freshness

Source record

NCT ID

NCT00482079

Original source

ClinicalTrials.gov

Source last updated

Mar 28, 2017

Ingested at

Jun 16, 2026

Internal sync

Jun 16, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00482079

Title

A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled Dose-Range Finding Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

Sponsor

Merck Sharp & Dohme LLC

Status

COMPLETED

Phase

Phase 2

Condition raw

Diabetes Mellitus, Type II

Condition normalized

Diabetes Mellitus, Type II

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Dipeptidyl peptidase-4 (DPP-4) inhibition

Target normalized

Dipeptidyl peptidase-4 (DPP-4) inhibition

Interventions

MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks

Public preview

Source record

MK0431, also known as sitagliptin phosphate, is positioned within the competitive landscape of Type 2 diabetes treatments, particularly among DPP-4 inhibitors. The study's completion indicates that Merck Sharp & Dohme LLC has advanced its understanding of MK0431's efficacy and safety profile. Given the increasing prevalence of Type 2 diabetes globally, successful outcomes could enhance market share against existing therapies, including other DPP-4 inhibitors and GLP-1 receptor agonists. The results may also support further development and potential combination therapies, aligning with current trends in diabetes management. Diligence should focus on market access strategies and potential pricing models in light of competitive pressures.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled Dose-Range Finding Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT00482079

Status

COMPLETED

Phase

Phase 2

Sponsor

Merck Sharp & Dohme LLC

Executive brief

Investment-Ready Snapshot

MK0431, also known as sitagliptin phosphate, is positioned within the competitive landscape of Type 2 diabetes treatments, particularly among DPP-4 inhibitors. The study's completion indicates that Merck Sharp & Dohme LLC has advanced its understanding of MK0431's efficacy and safety profile. Given the increasing prevalence of Type 2 diabetes globally, successful outcomes could enhance market share against existing therapies, including other DPP-4 inhibitors and GLP-1 receptor agonists. The results may also support further development and potential combination therapies, aligning with current trends in diabetes management. Diligence should focus on market access strategies and potential pricing models in light of competitive pressures.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 28, 2017
Internal syncJun 16, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00482079

Indication

Diabetes Mellitus, Type II

Modality

small molecule

Target

Dipeptidyl peptidase-4 (DPP-4) inhibition

Intervention

MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.